PUT NAME ON FRONT AND BACK
PUT ALL ANSWERS ON SCAN SHEET
NAME _____________________________________
SECTION ________________
1. The peripheral nervous system
A. Is composed of 43 pairs of nerves
B. Has both somatic visceral functions
C. Has paravertebral ganglia within it
D. Two of these
[E]. All of these
2. Thoracic spinal nerves
A. Have a visceral function
B. Have a somatic function
C. Have some neurons that are pseudounipolar
[D.] All of these
E. A & B
3. The first sacral spinal nerves
A. Only innervate dermatomes
B. Are part of the autonomic nervous system
C. Have efferent neurons within them that secrete ACH
D. All of these
[E.] A & C
4. The fourth cranial nerve
[A.] Trochlear
B. Trigeminal
C. Abducens
D. Facial
E. None of these
5. Cranial nerve which innervates the organ of Corti (hearing)
[A.] VIII
B. IX
C. VI
D. XI
E. Trochlear
6. Has a SVA function
A. I
B. IX
C. II
D. All of these
[E.] Two of these
7. Bell's palsy is associated with this cranial nerve
A. Vestibulocochlear
B. Abducens
[C.] VII
D. VI
E. V
8. The modality (type) of sensation as it is perceived
A. Is a function of the frequency of action potentials
in the afferent neuron
B. Is a function of the log of the receptor potential
[C.] Is a function of where it terminates in the CNS
D. All of these
E. Two of these
9. In the above drawing
A. This relationship would be typical of a tonic receptor
B. This relationship would be typical of a phasic receptor
C. This figure would look the same if the Y axis were
entitled "magnitude of receptor potential"
[D.] Two of these
E. All of these
10. The effector in the myotatic reflex
A. Annulospiral ring
B. Interfusal fiber
C. A-gamma fiber
D. A-alpha fiber
[E.] None of these
11. Motor pathway
A. Cortico-Pontile-Cerebellar
B. Rubrospinal
C. Tectospinal
[D.] Two of these
E. All of these
12. Associated with the dorsal column system
A. Decussation of the Pyramids
B. Ventral posterior lateral nucleus
C. Putamen
[D.] Ventro-basal complex
E. Red nucleus
13. Pathway which sends information about what is "intended"
in respect to muscle movement
A. Pyramidal
B. Spinal cerebellar
[C.] Cortico-Pontile-Cerebellar
D. Spinal thalamic
E. None of these
14. Tetanus toxin prevents release of this neurotransmitter
A. Aspartate
B. Serotonin
C. Glycine
[D.] GABA
E. Endorphins
15. Implicated as likely compound in endothelium
A. Substance P
B. GABA
C. Glycine
D. Serotonin
[E.] Nitric oxide
16. A disease that involves inflamation of the brain matter itself
A. Meningitis
B. Encephalitis
C. Reye's Syndrome
D. All of these
[E.] Two of these
17. The type of receptors on the celiac ganglion
A. Alpha-1
B. Muscarinic
[C.] N-1
D. N-2
E. None of these
18. Associated with sympathetic efferent pathways
A. Superior cervical ganglion
B. N-1 receptors
C. Alpha receptors
[D.] All of these
E. Two of these
19. Associated with sympathetic afferent pathways
A. Nor-epinephrine
B. Sensation of a full bladder
C. Thirst
D. Two of these
[E.] None of these
20. Type of receptors on visceral effectors
A. N-1
B. N-2
[C.] Muscarinic
D. All of these
E. Two of these
21. Receptor that binds ACH
A. Muscarinic
B. Nicotinic
C. Alpha
D. All of these
[E.] A & B
22. Enzyme that causes a precursor to be converted into L-DOPA
[A.] Tyrosine hydroxylase
B. Dopamine beta hydroxylase
C. Decarboxylase
D. COMT
E. None of these
23. The following could cause termination of the signal at post
ganglionic sympathetic sites
A. MAO in the synapse
[B.] Uptake 1
C. Alpha-1 pre-synaptic receptors
D. All of these
E. Two of these
24. Receptors associated with excitation
A. Beta-1
B. Alpha-1
C. N-2
[D.] All of these
E. A & B
25. Promotes emergencies
[A.] Sympathetic efferent pathways
B. Parasympathetic efferent pathways
C. Sympathetic afferent pathways
D. A & C
E. None of these
26. Primary neurotransmitter at post ganglionic sympathetic fibers
inervating the apocrine sweat glands
A. ACH
B. Epinephrine
[C.] Nor-epinephrine
D. Serotonin
E. None of these
27. Likely adrenergic receptors on urinary bladder
A. Alpha-1
B. Alpha-2
C. Beta-1
[D.] Beta-2
28. A drug that might be used to treat asthma
A. Anticholinesterase
[B.] Muscarinic blocker
C. Beta-2 blocker
D. All of these
E. Two of these
29. A drug that might be used as an antihypertensive
A. Alpha-2 blocker
B. B-2 blocker
C. Muscarinic blocker
D. Two of these
[E.] None of these
30. A drug that might be used in the treatment of glaucoma
A. Cholinomimetic
B. Anticholinesterase
C. Timolol sulfate
[D.] All of these
E. A & B
31. Another name for Flaxadil
[A.] Gallamine
B. Tropicamide
C. Reserpine
D. Clonidine
E. Terazosin
32. Part of the conductile portion of the heart
A. A.V. Node
B. Bundle of His
C. Myocardium
[D.] A & B
E. All of these
33. Area of low electrical resistance between adjacent cardiac
muscle cells
A. S.A. Node
B. A.V. Node
C. Purkinje Fibers
D. T-tubules
[E.] None of these
34. In the figure above
A. Part C is caused by an increase in K+ permeability
B. Increasing the duration of part B would ultimately increase
the release of more calcium from subsarcolemmal stores
C. The entire figure could be recorded from the A.V. node
D. All of these
[E.] Two of these
35. The pericardial sac is found between these two membranes
A. Epicardium and fibrous pericardium
B. Serous pericardium and fibrous pericardium
C. Epicardium and endocardium
D. Endocardium and serous pericardium
E. Epicardium and serous pericardium
[F.] Question thrown out no answer
36. Valve between the right and left ventricle
A. Bicuspid
B. Tricuspid
C. Semilunar
[D.] None of these
A = INCREASE OR GREATER THAN
B = DECREASE OR LESS THAN
C= NO EFFECT OR EQUAL TO
37. Number of spinal nerves with a somatic afferent function as
[B] compared to the number with a somatic efferent function
38. Number of neurons in the pyramidal pathway as compared
[B] to the number of neurons in the dorsal column system
39. Number of neurons in the cortico-pontile-cerebellar
[C] pathway as compared to the dentata-thalamo-cortico pathway
40. Number of cranial nerves with a visceral function as
[A] compared to the number of sacral spinal nerves with a
visceral function
41. Number of cervical spinal nerves with a sympathetic function
[C] as compared to the number of cervical spinal nerves with a
parasympathetic function
42. Length of preganglonic sympathetic neurons as compared to
[B] the length of preganglionic parasympathetic neruons
43. Length of a preganglionic fiber servicing a paravertebral
[B] ganglion as compared to a preganglonic fiber servicing a
collateral ganglion
44. Affinity of alpha receptors for epinephrine as compared to
[A] beta receptors affinity for epinephrine
45. Effect of parasympathetic stimulation on the contraction
[A] of the ciliary muscle
46. Effect of beta stimulation on the diameter of blood vessels
[A]
47. Effect of stimulating the alpha receptors on lacrimal glands
[C] on the subsequent production of tears
48. Effect of triemethaphon (Arfonad) on skeletal muscle
[C] contraction
49. Effect of Aldomet on sympathetic activity
[B]
50. Effect of Clonidine on heart rate
[C]
51. Effect of terazosin (Hytrin) plus epinephrine on heart rate
[A]
52. Effect of oxybutynin chloride (Ditropin) plus Urecholine on salivation
[C]
53. Effect of Eserine plus ACH on gastrointestinal activity
[A]
54. Effect of propranolol (Inderal) plus isoproterenol on
[C] the diameter of the bronchi
55. Effect of Dobutrex on heart rate
[A]
56. Amount of calcium stored in sarcoplasmic reticulum (S.R.)
[B] of cardiac muscle as compared to the amount of calcium stored
in the S.R. of skeletal muscle
57. Effect of increasing trigger CA++ on stroke volume
[A]
58. Effect of muscarinic stimulation on the rate at which K+
[B] permeability declines during the prepotential